This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 Apr;365(9468):1363-4.

doi: 10.1016/S0140-6736(05)66348-9.

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

Uberto Pagotto¹, Renato Pasquali

Affiliations

Affiliation

¹ Endocrine Unit, Department of Internal Medicine and Gastroenterology, and Center for Applied Biomedical Research, S Orsola-Malpighi General Hospital, Università Alma Mater Studiorum, Bologna 40138, Italy. pagube@med.unibo.it

PMID: 15836868
DOI: 10.1016/S0140-6736(05)66348-9

Comment

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

Uberto Pagotto et al. Lancet. 2005 Apr.

. 2005 Apr;365(9468):1363-4.

doi: 10.1016/S0140-6736(05)66348-9.

Authors

Uberto Pagotto¹, Renato Pasquali

Affiliation

¹ Endocrine Unit, Department of Internal Medicine and Gastroenterology, and Center for Applied Biomedical Research, S Orsola-Malpighi General Hospital, Università Alma Mater Studiorum, Bologna 40138, Italy. pagube@med.unibo.it

PMID: 15836868
DOI: 10.1016/S0140-6736(05)66348-9

No abstract available

PubMed Disclaimer

Comment on

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Van Gaal LF, et al. Lancet. 2005 Apr 16-22;365(9468):1389-97. doi: 10.1016/S0140-6736(05)66374-X. Lancet. 2005. PMID: 15836887 Clinical Trial.

Similar articles

Update on rimonabant--a selective cannabinoid CB1 antagonist.
Boyd ST, Fremming BA. Boyd ST, et al. Ann Pharmacother. 2006 May;40(5):994. doi: 10.1345/aph.1G713. Epub 2006 Apr 25. Ann Pharmacother. 2006. PMID: 16638915 No abstract available.
Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V. Di Marzo V. Nat Clin Pract Cardiovasc Med. 2008 Oct;5(10):610-2. doi: 10.1038/ncpcardio1319. Epub 2008 Aug 12. Nat Clin Pract Cardiovasc Med. 2008. PMID: 18695695 No abstract available.
Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Steinberg BA, Cannon CP. Steinberg BA, et al. Am J Cardiol. 2007 Dec 17;100(12A):27P-32P. doi: 10.1016/j.amjcard.2007.10.011. Am J Cardiol. 2007. PMID: 18154743 Review.
[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM, Jukema JW, Peters RJ. Boekholdt SM, et al. Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Ned Tijdschr Geneeskd. 2007. PMID: 18161262 Review. Dutch.
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group. Van Gaal LF, et al. Lancet. 2005 Apr 16-22;365(9468):1389-97. doi: 10.1016/S0140-6736(05)66374-X. Lancet. 2005. PMID: 15836887 Clinical Trial.

See all similar articles

Cited by

Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.
Jorgačević B, Mladenović D, Ninković M, Vesković M, Dragutinović V, Vatazević A, Vučević D, Ješić Vukićević R, Radosavljević T. Jorgačević B, et al. Oxid Med Cell Longev. 2015;2015:842108. doi: 10.1155/2015/842108. Epub 2015 May 11. Oxid Med Cell Longev. 2015. PMID: 26078820 Free PMC article.
Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.
Heppenstall C, Bunce S, Smith JC. Heppenstall C, et al. Nutr J. 2012 Jul 23;11:50. doi: 10.1186/1475-2891-11-50. Nutr J. 2012. PMID: 22824101 Free PMC article.
Rise and fall of anti-obesity drugs.
Li MF, Cheung BM. Li MF, et al. World J Diabetes. 2011 Feb 15;2(2):19-23. doi: 10.4239/wjd.v2.i2.19. World J Diabetes. 2011. PMID: 21537456 Free PMC article.
Drug treatment for obesity in the post-sibutramine era.
Cheung BM. Cheung BM. Drug Saf. 2011 Aug 1;34(8):641-50. doi: 10.2165/11592040-000000000-00000. Drug Saf. 2011. PMID: 21751825
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.
Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH. Nogueiras R, et al. Diabetes. 2008 Nov;57(11):2977-91. doi: 10.2337/db08-0161. Epub 2008 Aug 20. Diabetes. 2008. PMID: 18716045 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information